A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis (BREEZE-AD7)

I4V-MC-JAIY -

The purpose of this study is to evaluate the efficacy and safety of baricitinib incombination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Atopic Dermatitis
What the trial is testing?
Baricitinib, Topical corticosteroid
Could I receive a Placebo?
Yes
Enrollment Goal
329
Trial Dates
Nov 16, 2018 - Aug 22, 2019
How long will I be in the trial?
The study will last about 25 weeks and may include up to 9 visits.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.